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Expression of the Dopamine D2 Receptor Gene 
in Brain* 
James H. Meador-Woodruff, and Alfred Mansour 
The cloning of the dopamine (DA) De receptor now permits the characterization a ~  
regulation of D2 messenger RNA (mRNA) in the brain. In this article, the authors describe 
their studies delineating the distribution of D2 receptor mRNA in the rodent and primate 
brain, and compare the distribution of message to D, receptor binding sites. The effects 
of chronic DA agonist and antagonist treatment on Dz receptor mRNA are also presented, 
and provide insights into receptor regulation. Finally, the autoreceptor role of Dz re- 
ceptors located in the midbrain is examined with a combination of 6-hydroxydopamine 
lesions and anatomic colocalization studies with tyrosine hydroxylase. These preclinical 
results provide a framework for subsequent investigation into the nature of D2 receptor 
gene expression in postmortem brains from patients with disorders putatively associated 
with dopaminergic dysfunction, especially schizophrenia. They also lay the groundwork 
for a more profound understanding of DA neurocircuitry by combining molecular bio- 
logical and traditional anatomical techniques. 
Introduction 
Dopamine (DA) is the neurotransmitter most commonly associated with the pathogenesis 
and symptoms of schizophrenia (Creese et al 1976; Seeman et al 1976; Snyder 1976). 
Anatomically, the DA system is well suited for the regulation of affect and behavior, 
with midbrain DA cell groups (the substantia nigra and the ventral tegmental area [VTA]) 
projecting to a number of forebrain structures, most notably the basal ganglia, many 
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accumbens, and limbic cortex, as well as to much of the neocortex (Cooper et al 1986). 
Dysregulation of these projections, especially the mesocorticolimbic system originating 
in the VTA, has been implicated in this illness. In its original form, the so-c~ed dop~ine  
hypothesis of schizophrenia postulated that there was excessive dopandnergic tone in 
these projections, associated with the symptoms seen in the disease (Cruse et al 1976; 
Seeman et al 1976; Snyder 1976). Subsequent refinements have been made to this hy- 
pothesis, postulating a diminished tone of these projections, especially to the dorsolateral 
prefrontal cortex, resulting in relative hyperactivity in subcortica! structures secondary to 
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altered regulation of descending cortical-subcortical pathways (Berman et al 1988; Wein- 
berger et al 1988). Despite the existence of these ~u'ious permutations of the DA hy- 
pothesis, the nature of the dopaminergic lesion in schizophrenia has yet to be identified. 
Direct studies of DA functioning in schizophrenia have been inconclusive at best. 
Early attempts were_ designed to examine levels of circulating growth hormone and 
prolactin in patients with this illness, both at rest and following physiological challenge 
(Meltzer et al 1974; Johnstone et al 1977; Brown and Laughren 1981; Kleinman et al 
1982; Rinieris et al 1985; Ettigi et al 1976; Tamminga et ai 1977; Rotrosen et al 1979). 
These hormones are both regulated by DA via the tuberhypophyseal pathway, and the 
strategy in studying them has been to see if there might be a global dysfunction of all 
brain DA systems, possibly reflected in the dysregulation of the pituitary system and 
being manifested in circulating levels of these hormones. The results of these studies 
have beet, contradictory, and have never clearly established a dysfunction of this dien- 
cephalic DA system in schizophrenia. The major flaw of these studies is that only the 
mesencephalic systems may be dysfunctional in schizophrenia, with the others remaining 
intact. Thus, the regulation of prolactin and growth hormone may be normal in schizo- 
phrenia, while the mesocorticolimbic and/or nigrostriatal projections may be dysfunc- 
tional. 
Other indexes of dopaminergic activity have also been meastLred to ~-,-~her bolster the 
dopamine hypothesis. These include the measurement of dopamine itself, its metabolites, 
and DA receptors in postmortem brains from schizophr~nics. Here, again, findings have 
been inconsistent, and may be related to a previous history of neuroleptic exposure. 
Dopamine itself has been reported to be increased or unchanged in the caudate, putamen, 
and the nucleus accumbens. Several DA metabolites have also been studied in these 
structures; dihydroxyphenylacetic acid (DOPAC) is usually reported to be unchanged, 
but homovanillic acid (HVA) has on occasion been reported to ~ elevated, perhaps 
reflecting an increased rate of DA turnover (recently reviewed by Jaski-v and Kleinman 
1989). 
Much effort has been focused on the DA receptors in schizophrenia, especially~the 
D: receptor, because of the good correlation between D2 receptor binding and the phar- 
macological efficacy of the neuroleptic drugs (Creese et al 1976; Seeman et al 1976). 
Although an occasional study reports no changes in D2 receptor number in the basal 
~ n M ~ , l - ' ~  d.i., . . . . . . . . . .  l k  ! 2 - - - -  - -  g '  sa-s-,, ,  ,,v ovc~w.vmau~ majority ot reports demonstrate an increase in the number of 
this receptor type in these structures (Seeman et al 1987; Lee and Seeman 1980; Cross 
et al 1981; Mackay et al 1982; Seeman et al 1984). This finding, however, may be related 
to previous neuroleptic history, since chronic exposure to antipsychotic medications is 
likely to cause an upregulation of these receptors (Burt et al 1977; Chipkin et al 1987; 
MacLennon et al 1988). More recently, efforts have been made to study D2 receptor 
density in vivo, in living patients using positron emission tomography. Conflicting results 
have been reported here as well, with one group (Wong et al 1986) indicating that the 
number of D2 receptors is increased in the basal ganglia of drug-free schizophrenics and 
several other groups (Martinot et al 1990; Farde et al 1990) reporting no change in this 
marker. These exciting results will need to be replicated, but this technique at least 
provides one method of circumventing the problem of previous neuroleptic exposure. 
Unfortunately, the level of resolution possible with these in vivo studies is very poor; 
hence the continuing need for well-designed postmortem studies. 
Recent advances in molecular biology now permit a more detailed examination of the 
DA systems in brain. The DA receptors have been recently cloned and investigations 
related to the distribution and regulation of the messenger RNA (mRNA) encoding these 
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receptors are now possible. The cloning of the rat DA D2 receptor was or ig :~ly  reported 
by Bunzow and coworkers (1988). Using the hamster 1~2-adrenergic receptor gene as a 
probe, a partial D2 receptor clone was isolated from a rat genomJc libr, a'y. This gene 
fragment was subsequently used as a probe to identify a full-length rat brain cDNA clone. 
This D2 receptor cDNA was cloned into a eucaryotic expression vector ~ the resulting 
construction used to transfect a mouse fibroblast cell line, and the resulting pharmaco- 
logical profile of the expressed receptor was characteristic of a D2 receptor. This, combined 
with mRNA distribution results from Northern blot analysis, and the conservation of key 
residues found in all catecholamine receptors for which the sequence is known, strongly 
supported the identification of the Bunzow clone as encoding ~e  D2 DA receptor. 
Shortly after the original cloning of the rat D2 receptor, a number of groups reported 
that instead of one, there are at least two distinct forms of D2 receptor ~ A ,  
presumably at least two different translation products (Monsma et al 1989; Dal Toso et 
al 1989; Giros et al 1989; Selbie et al 1989). The D2 receptor gene was found to be 
considerably different from other catecholamine receptor genes that had been identified 
tO date. The D2 receptor gene contains a number of introns and a particularly long third 
cytosolic loop (Dal Toso et al 1989; Grandy et al 1989), quite unlike the fl2-a~nergic 
and other similar seven transmembrane domain receptor genes, which contain no introns 
in their coding regions, and have a much shorter third c~osolic loop (Emorine et al 1987; 
O'Dowd et al 1989). The D~ receptor gene, cloned more recently, is s ~ a r  to the [32- 
adrenergic receptor gene in these respects (Dearry et al 1990; Zhou et al 1990; Sun~ara 
et al 1990; Monsma et al 1990). 
The presence of introns within the D2 receptor gene suggests the possibility of variants 
of the receptor due to alternate splicing of the gene during transcription. The two different 
forms of the D2 receptor that have been identified thus far are in fact the result of different 
message processing. The original clone that was reported by Bunzow et al (1988) was 
87 bases (29 amino acids) shorter than the second form that was subsequently identified; 
the difference between these two forms is due to the inclusion or exclusion of exon 5 in 
the final transcripts. The current convention is that the originally cloned, shorter cDNA, 
is identified as the D2~ receptor, and the longer message, which includes the 87 base pair 
region encoded by exon 5, is termed the D2~ receptor. 
We have been actively involved in the characterization of the mRNA encoding the 
DA D2 __receptor(s) wit_bin the an~J.om.ic context of the rodent and pri~mate brain using in 
situ hybridization techniques. In this article, we describe some of our findings in this 
area, including the mapping of the distributions of D2 receptor mRNAs in brain, the 
comparison of the distribution of message with D2 receptor binding, and selected regu- 
latory studies. These results lay the framework for subsequent investigations of the nature 
of D2 receptor gene expression in postmortem brains derived irom individuals who had 
suffered from schizophrenia. Although much of the data contained in this report is 
unpublished~ in the interest of chronological completeness, we have reviewed some of 
our previously reported data (Meador-Woodruff et al 1989; Mansour et al 1990a). 
Materials and Methods 
Animal Preparation 
For mapping studies (in situ hybridization and receptor autoradiography), b ~ s  of male 
Sprague-Dawley rats (250 g) that had been killed by decapitation were rapidly removed. 
Brains of old-world monkeys (Macaca mulatta) were similarly removed following ke- 
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tamine anesthesia and cut into l-2-cm coronal slabs. Whole rat brain and monkey tissue 
were frozen in isopentane ( -  30°C) for 30 or 120 see, respectively. Frozen tissue was 
cryostat-sectioned (15-20 Ixm) and thaw-mounted onto polylysine-subbed microscope 
slides. These sections were maintained at - 80"C until the time of hybridization or receptor 
autoradiography. 
For studies of pharmacological regulation of D2 receptor mRNA, male Sprague- 
Dawley rats (250-350 g) were treated with either haloperidol or apomorphine (6 animals 
per group). Haloperidol was administered subcutaneously at a dose of 2.0 mg/kg/day for 
a total of 14 days. Apomorphine was given subcutaneously twice daily at a dose of 5.0 
mg/kg/dose for 7 days. For each drug, a vehicle-treated control group (n -- 6) was 
employed. The brains of these animals were removed and processed as described above. 
For studies involving irnn~unohistochemistry in conjunction with in situ hybridization, 
male Sprague-Dawley rats (250-350 g) were anesthetized with sodium rentobarbitol (50 
mg/kg, intraperitoneally), and their cardiovascular systems were flushed with 50 ml of 
ice-cold 0.9% saline. Following the removal of red blood cells, animals were perfused 
via the aorta with O. 1 mol/L phosphate-buffered 4% formaldehyde (pH 7.4) for 10 rain. 
The brains were then removed and blocked, and refrigerated overnight in phosphate- 
buffered 15% sucrose, and then frozen in liquid nitrogen (-70"C).  Five-micron brain 
sections containing the substantia nigra and VTA were thaw-mounted on subbed micro- 
scope slides and further processed for immunohistochemistry and in situ hybridization. 
For animals given 6-hydroxydopamine (6-OHDA) lesions, male Sprague-Dawley rats 
(n = 9) were given a unilateral infusion of 6-OHDA into the medial forebrain bundle 
(8 I~g in 4 Ixl) after pretreatment with 25 mg/kg desmethylimipramine (Mansour et al 
1990b). These animals were killed 14 days later, and their brains removed and processed 
as described above for the mapping studies. 
Tissue samples for RNA protection assays were conservatively dissected from the 
brains of male Sprague-Dawley rats that had been killed by decapitation. Pituitaries and 
dissected striatum were removed on wet ice, and then immediately frozen on dry ice and 
stored at -80°C until further processing. 
In Situ Hybridization 
In situ hybridization was performed using [35S]-labeled riboprobes, o r  [32p]. or [3sS]- 
labeled oligonucleotides. Specific assay details have been previously described (Meador- 
Woodruff et al 1989; Ma,~our et ai i990a). Brief details of each assay ~ given below. 
The determination of total D2 receptor mRNA was made using [3sS]-labeled riboprobes 
synthesized from a Sac l-Bgl lI fragment of a rat D2 receptor cDNA (Bunzow et al 1988). 
This probe is a 495 base region corresponding to the third cytosolic loop and the sixth 
and seventh transmembrane domains of the rat D2 receptor. This region was selected 
because the greatest degree of dissimilarity between the catecholamine receptors occurs 
in the third cytosolic loop, thus providing a greater degree of probe specificity. This probe 
is 3' to the exon encoding the 29 amino acids that distinguish D2~ from D2~ mRNAs, 
hence recognizing both forms, or total 1:)2 receptor mRNA. For rat studies, hybridization 
was in 75% formamide buffer at 55°C, with the final posthybtSdization wash at 55°C in 
water (60 rain), as we have previously described (Meador-Woodruff et al 1989). For 
monkey experiments, the same in situ protocol was used, except hybridization took place 
in 50% formamide buffer, and the final posthybridization wash (60 min) was at 55°C in 
9.5 × SSC (300 mmol/L NaCI, 30 mmol/L sodium citrate, pH 7.2). 
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Messenger RNA encoding the longer isoform of the DA !)2 receptor (D2~) was vis- 
ualized using a fragment of a rat D2 receptor eDNA, which had been subcloned into 
pGEM4. This plasmid generates a 78 base riboprobe that is completely con~ned ~thin  
the 87 bases comprising exon 5 of the rat D2 receptor gene, thus providing a probe that 
is D2~-specific. Hybridization was performed in 75% formamide buffer at 5 5 ~ ,  with a 
final 60-min posthybridization wash in 0.5 x SSC at 55°(2. 
The mRNA encoding the short isoform of the D2 receptor (D~) was visualized using 
a [3SSl-labeled oligonucleotide (AGCTCGGC~AGCATCCTTGAGTGGTGTC' IT-  
CAG). This 30 base probe is complementary to the 15 bases on either side of the 87 
base insert of the longer isoform of the i)2 receptor. In the case of the longer ~ ,  Lhis 
oligonucleotide will hybridize to 15 bases, but in the case of the shorter isoform, it 
form a 30 base pair RNA-DNA hybrid. The hybridization conditions were designed to 
not allow visualization of a 15 base pair hybrid, but the longer 30 base hybrids would 
be retained (Wood et al 1984). Prehybridization of sections was performed as previously 
described (Meador-Woodruff et al 1989; Mansour et al 1990a), and hybridization was 
performed in 50% formamide buffer at 42°(? overnight. Posthybridization washes were 
in 4 x SSC (three washes of 10 min each, at 22°C), a 10-min, 22°C rinse in 3 moL/L 
TMACi buffer (3 mol/L tetramethylammonium chloride, 50 mmol/L "Iris (pH 8.0), 2 
mmoL'L EDTA, 0.1% sodium dodecy! sulfate), followed by a 60-rain wash at 65°C in 
the 3-mol/L TMACI buffer. After a final 10-rain rinse in 4 x SSC (22°C), slides were 
dried and processed as other in situ hybridization sections. The specificity of this assay 
was confirmed by generating RNAs either containing or not containing the 87 base insert, 
electrophoresing these RNAs on standard Nortbem gels, and transferring the RNA bands 
to Nytran membranes. These membranes were then treated with the above protocol, and 
at posthybridization washes above 50°-55°(2, only D~ (short isoform) mRNA was de- 
tectable. 
Visualization of tyrosine hydroxylase (TH) mRNA was accomplished by h y b r i d ~ g  
with a [32p]-labeled oligonucleotide (CGGACGCK]TCTCCGCK;TGACCGTCCTTC). 
Hybridization was performed in a 50% formamide buffer at 45°C, and posthybridization 
washes were in 4 x SSC (22°C) and 2 x SSC (45°C, 60 min). 
Dz Receptor Autoradiography 
D2 receptor binding was visualized as previously reported (Mansour et al 1990a). Briefly, 
receptor autoradiography was performed using [3H] raclopride (5.7 nmol/L), a selective 
D2 antagonist, and labeled slides were apposed to tritium-sensitive Hyperfilm (Amersham) 
for 1-2 months tc produce the images in this report. 
RNase Protection Assay 
Total RNA from frozen samples of striatum and pituitary was extracted using a modified 
guanidinium-isothiocyanate (GITC) method first described by Chirgwin et al (1979). 
Varying amounts of total RNA were hybridized with a 174 base pair [32p]-labeled cRNA 
probe spanning the 87 base pair insert (exon 5) of the D213 isoform and extending an 
additional '~" '---- p ~  ~" "" . . . .  "-- "-- ' -  hybridizafi -" o t ua:s¢ in  t h e   u u r ,  t ; u o n ,  r,,at;n Off r e a c t i o n  c o n s i s t e d  o i  
30 ttl: 6 ttl 5 x hybridization buffer (0.2 mol/L PIPES, pH 6.4, 2.0 mol/L NaCl, 5.0 
mmol/L EDTA), 15 I~l deionized formamide containing 25 fmol of cRNA probe, and 9 
td total RNA (3-48 Izg) resuspended in water. Samples were denatur~l (85°C for 5 rain) 
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and incubated overnight (60°C). Hybridization reactions were then cooled to room tem- 
perature and RNase digested (22*(2, 30 min) with 200 Ixi buffer (10 mmol/L Tris-HCi, 
pH 7.5, 5 mmol/L EDTA, 0.2 mol/L NaCI, 0.1 mol/L LiCI) containing RNase A (10 
I~g/ml). Digestion was terminated with the addition of 10 p,! 20% (w/v) sodium dodecyl 
sulfate and 10 p,l proteinase K (10 mg/mi) at 37°C for 30 rain. Samples were then phenol- 
chloroform extracted, and electrophoresed on a 8% polyacrylamide denaturing gel. 
Tyrosine Hydroxylase lmmunohistochemistry 
Frozen sections of 4% formaldehyde-fixed brain were allowed to air dry (22°C) and 
incubated with normal goat serum (NGS, from GIBCO) at a dilution of 1/30 at 37"C for 
10 min. NGS was then removed and the slides were incubated with a rabbit TH antibody 
diluted 1/1000 in 0.02-mol/L phosphate-buffered saline (PBS) and 0.3% Triton X-100 
for 1 hr at 37°C, and overnight at 4°C. The following day, brain sections were washed 
in PBS and incubated with a goat-antirabbit serum (Amel) at 1/1000 dilution for 30 rain 
at 37°(2, and overnight at 4°C. On the third day the slides were washed in PBS and 
incubated with anti-horseradish peroxidase serum diluted 1t1000 (37°C, 40 rain). The 
brain sections were again rinsed in PBS and incubated at 37"C with horseradish peroxidase 
(HRP, 4 I~g/ml) tbr 40 min. The HRP reaction product was visualized by treating the 
slides with 0.03% H202 and 0.125 mg/ml diaminobenzidine for 15 rain at 22°C with 
constant stirring. The slides were washed in water, osmicated (2% OsO4), dehydrated 
through graded alcohols and coverslipped. Sections were analyzed and photographed with 
a Leitz Orthoplan microscope. 
Image Analysis 
Quantitation of X-ray images was performed using a computer-based image analysis 
system, as previously described (Herman et al 1989). Total optical densities for regions 
of interest were determined. Optical density values were then converted to disintegrations 
per minute by interpolating values from a standard curve of [35S]-containing brain paste 
standards of known radioactivity. 
Results 
Localization of D2 Receptor mRNA in Rat Brain 
Using [35S]-labeled riboprobes corresponding to the third cytosolic loop and the sixth and 
seventh transmembrane domains of the rat D2 receptor, we examined the distribution of 
this message using in situ hybridization (Meador-Woodruff et al 1989). This mRNA was 
found in all of the traditional dopaminoceptive regions of the brain, with particularly 
dense labeling in the caudate-putamen, nucleus accumbens, olfactory tubercle, and pir- 
iform cortex (right panels, Figures l and 2). Moderate labeling was observed in the 
hypothalamus and much of cortex, as well as a number of other limbic structures, including 
the lateral septum, hippocampus, and amygdala. The labeling in some brain regions was 
heterogeneous, and showed rostral-caudal and medial-lateral differences (Figure. I E). 
In addition to these dopaminoceptive regions, high levels of this mRNA were observed 
in several of the DA-containing cell groups (Figures IF and 2). Specifically, high levels 
were observed in the substantia nigra (pars compacta), VTA, and zona incerta. The 
presence of this mRNA in these structures strongly suggest~ autoreceptor synthesis. 
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Comparison of the Distributions of D2 Receptor mRNA and Binding Sites 
Using sequential adjacent sections through the rat brain, we next compared the dis~bufion 
of D2 receptor mRNA and D2 binding sites (Figures I and 2). A high degree of concordaace 
was observed between these distributions in a number of structures, including the caudate- 
putamen, globus pallidus, nucleus accumbens, olfacto~ tubercle, and the midbrain DA- 
containing cell groups, the substantia nigra and VTA. Several areas manifested dissimilar 
distributions; these included the olfactory bulb, hippocampus, and many regions of cortex 
(Mansour et al 1990a). 
Localization of Dz Receptor mRNA in Primate Brain 
Following these studies in the rat, we began efforts to map this mRNA in the monkey 
brain. As our ultimate goal is to examine the expression of the DA receptor genes in 
postmorte~a schizophrenic brains, we felt that it was important to be able to visualize 
this parUcldar message in primate neural tissue. Using the in situ hybridization protocol 
and the rat D2 receptor probe described above, we mapped the distribution of this mRNA 
in the brain of the old world monkey, Macaca mulana (Figure 3). As in the case of the 
rodent, high levels of expression were observed in the traditional dopaminoceptive regions, 
including the caudate and putamen, as well as in a number of limbic regions such as the 
amygdala, hippocampus, various regions of cortex, and the lateral septum. As in the case 
of the rat, the globus pallidus had considerably less message than the caudate or the 
putamen. D2 receptor mRNA was also observed in the substantia nigra, as was seen in 
the rat, again suggesting autoreceptor synthesis. 
Multiple Forms of the DA D2 Receptor 
With the identification of the D2,, and D2a variants, we next turned our attention to the 
possibility of mapping these two fGrms in the brain using in situ hybridization. Our 
original mapping efforts described above used riboprobes corresponding to exons 6 and 
7, all of which is 3' to the exon responsible for the variability. Thus, our initial maps 
visualized both D2~ and D2a mRNAs. 
To examine the relative concentrations and distribution of the Dz~ and D213 forms, we 
first performed solution phase protection assays to determine if we could identify mRNA 
bands corresponding to these two forms (Figure 4). A probe capable of distinguishing 
both isoforms identified both 024 and D213 in a number of brain regions. The longer 
isoform, D2a, was considerably more abundant in all regions studied, consistent with the 
results of other groups (Monsma et al 1989; Dal Toso et al 1989; Giros et al 1989; Chio 
et ai 1990; Rao et al 1990). Although present at a considerably lower abundance, D2~ 
was identifiable in every region as well, including dopaminergic and dopaminoceptive 
brain areas. 
Following the demonstration of these two forms in tissue homogenates, we next 
attempted to demonstrate the presence of each form in brain using in situ hybridization. 
We first compared the distribution of total D2 mRNA with that of the more abundant 
(longer) form, O213- Total D2 rrLRNA was visualized using the 495 base riboprobe cor- 
responding to exons 6 and 7, which code for the third cytosolic loop and the sixth and 
seventh transmembrane domains. The distribution of D213 mRNA was determined using 
the same in situ hybridization protocol, with a 78 base riboprobe encoded exclusively by 
exon 5; this probe recognizes only D2a, not the short form, D2~. Representative images 
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of this c o m ~ s o n  ate shown in Figures 5 and 6. In the forebrain (Figure 5), the distribution 
of total D, receptor mRNA and exclusively D2a mRNA appear identical, with dense 
labeling in the caudate-putamen, nucleus accumbens, and olfactory tubercle. In addition, 
in several DA-containing cell groups, identical labeling was observed: high levels of ~otal 
D2 receptor mRNA as well as D2~ receptor message were observed in the substanfia nigra 
(pars compacta), VTA, and zona incerta (Figure 6), probably encoding DA autoreceptors. 
The demonstration of simda~ patterns of total D, receptor and D~ receptor messages is 
not unexpected, given that we and others (Monsma et al 1989; Dal Toso et al 1989; Giros 
et al 1989; Chio et al 1990; Rao et al 1990) have demonstrated that both D~ and D2~ 
receptor messages coexist in all brain regions studied, and that D~ receptor message is 
the most abundant in each region studied. Given this, one would expect total D2 receptor 
and D2a receptor mRNAs to have sinfilar distributions. 
More recently, we have developed an assay specific for D~ receptor mRNA (Figure 
7). The basis of this particular assay is a 30 base long, [3sS]-labeled oligonucleofide and 
a wash stringency that is calibrated to dissociate 15 base pair hybrids formed with D2~ 
but not the 30 base pair hybrids formed with D~, thus allowing the visualization of 
exclusively D2,, receptor mRNA. Using the nigrostriatal system as a model, a comparison 
of the distributions of D2a and D: a receptor mRHAs are presented in Figure 7. Both the 
nigra and the caudate-putamen can be seen to contain both isoforms of this message, 
supporting the finding of codistribution based on gel analyses. 
Pharmacological Regulation 
After these mapping studies, we next attempted to pharmacologically regulate these 
messages, using classical DA agonist-antagonist treatment. Chronic treatment with apo- 
morphine or haloperidol resulted in no significant change in total D2 receptor mRNA 
levels in either the caudate-putamen or in the substantia nigra, as shown in Figure 8. 
Demonstration of Midbrain Autoreceptors 
Several experiments we~ undertaken to explore whether the D2 receptor could have an 
autoreceptor function in the brain. Thin sequential sections of the rat brain, taken at the 
level of the midbrain, were probed for either D2 receptor mRNA or TH immunostalning 
(Figure 9). Under both low- and high-power views, the concordance between these two 
markers was very high, thus suggesting that most DA-producing cells (i.e., positive for 
TH) also are capable of encoding D2 receptors. 
To further confirm this finding, we performed unilateral 6-OHDA lesions in the medial 
forebrain bundle. As can be appreciated in Figure 10, these lesions produced a total loss 
of both D2 receptor binding and D2 receptor mRNA, as well as TH mRNA in the midbrain 
DA cell groups. This again strongly supports the notion that the D2 receptor mRNA seen 
in the midbrain encodes autoreceptors. 
Discussion 
These findings demonstrate that D2 receptor mRNA is distributed in both traditional 
dopaminoceptive as well as DA-containing regions of the rodent and primate brain, that 
this distribution is explainable based on the known distribution of D2 receptor binding 
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Figure 1. Comparison of the distribution of D2 receptor binding and messenger RNA (mRNA) in 
the rat brain. A, D: coronal sections through the rostral forebrain. Note similar patterns of D2 
binding and message in the caudate-putamen (CPU), nucleus accumbens (ACB), and the olfactory 
tubercle (OTU). There is faint labeling of D2 receptor mRNA in the cortex (CTX) that is not 
appreciated by receptor autoradiography. B, E: coronal sections at the level of the globus pallidus 
(GP). Note similar distributions of message and binding in the CPU, GP, and OTU, but distinct 
differences in the hippocampus (HPC) and cortex. C, F: coronal sections at the level of the mid~ain. 
Note similar distributions of D2 receptor binding and mRNA in the pars compacta of the substantia 
nigra (SN) and ventral tegmental area (VTA). This labeling probably reflects synthesis of DA 
autoreceptors in these two structures. As in the panel above, distract differences can be seen in the 
hippocampus. 
Figure 2. Horizontal sections 
through the rat brain compar- 
ing the distributions of (A) D= 
receptor binding and (B) D2 
receptor mRNA. In addition 
to the structures visualized in 
coronal sections in Figure !, 
note the presence of D2 re- 
ceptor mRNA in the zona in- 
certa (ZI). As in the case of 
the SN and VTA, this mes- 
sage is probably encoding au- 
toreceptors. 
Figure 3. Distribution of D2 receptor mRNA in a coronal section from the old world monkey. Note the 
similarity of the distribution of this message with that found in the rat brain, especially in elements of the 
nigrostriatal system. Both dopaminoceptive and DA-containing regions are visualized, reflecting primarily 
postsynaptic receptors and autoreceptors, respectively. Abbreviations: C, caudate nucleus; P, putamen; GP, 
globus pallidus; SN, substantia nigra; Th, thalamus; LGN, lateral geniculate nucleus; DG, dentate gyros; H, 
hippocampus. Non-D, mRNA-labeled structures are also identified for anatomic orientation: cc, corpus 
callosum; f, fornix; ic, internal capsule. 
D2 mRNA 
1+187 
PITUITARY S T R I A T ~  
16 32 48 3 9 18 
D 2 mRNA 
1-187 
Figure 4. RNase protection assay demonstrating the presence of both D2~ and D2~ receptor mRNAs 
in rat brain. Extracts of pituitary and striatum were assayed; total RNA (in lag) for each l ~  is 
shown at the top of the gel. Note that D2~ C + 87") is the predominant form of D2 receptor mRNA, 
although a faint band corresponding to D2, (" -87")  receptor mRNA can also be appreciated. 
i  !II iii!!i! 
Figure 5. Comparison of the distributions of the messenger RNAs encoding both total D2 receptor 
mRNA (left panel) and D213 receptor mRNA (right panel) in the forebrain of the rat. The probe 
used for identifying total I)2 receptor mRNA was generated from cDNA corresponding to exons 6 
and 7, and the probe used for visualizing D213 receptor mRNA corresponded to exon 5; see text 
for further details. Note the apparent identical distributions of these messages, which is expected, 
as D2~ mRNA is the predominant form of the total D2 receptor mRNA in these structures. Abbre- 
viations: CPU, caudate-putamen; ACB, nucleus accumbens; OT, olfactory tubercle; P, piriform 
cortex. Although faint in the left panel (total message), piriform cortex is identifiable with both 
cRNA probes. 
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Figure 6. Comparison of the distributions of total 02 and Dzp receptor mRNAs in DA-containing 
cell groups. The probes described for Figure 5 were used to generate these images. As in the case 
of the forebrain, note the apparent identical distributions of these messages in these DA-containing 
regions. It is likely that at least some of the DA autoreceptors are D2p receptors. Abbreviations: 
SNc, substantia nigra pars compacta; VTA, ventral tegmenlal area; Zl, zona incerta. 
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Figure 7. Comparison of the 
distributions of ~ ~ o  iso- 
forms of the D_-, receptor, D:~ 
( -  e5) and D.~ ( + eSL in 
nigrostriatal system o f ~  rat. 
Note similar dish,'ibutions in 
both the caudate-pu~men and 
in the substanfia nigra; faint 
labeling of the ~ppocampus 
can also be apprechted in h~ 
bottom two p~els.  Postsyn- 
aptic as v~ell as amoreceptors 
in the nigrostriatal system 
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Figure 8. Effect of chronic haloperidol CA) and apomorphine (B) treatment on D2 rec.eptor mRNA in the 
caudate-putamen and the substantia nigra. Results are expressed as means -+ SEM, and are percemag,.:s of 
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F i g u r e  1 0 .  E f f e c t  o f  6 - h y d r o x y d o p a m i n e  ( 6 - O H D A )  l e s i o n s  o n  t h e  s u b s t a n t i a  n i g r a  o f  t h e  r a t .  R a t s  
r e c e i v e d  u n i l a t e r a l  6 - O H D A  i n j e c t i o n s  i n t o  t h e  m e d i a l  f o r e b r a i n  b u n d l e .  N o t e  t h e  d i s a p p e a r a n c e  
o f  D e  r e c e p t o r  b i n d i n g  ( A )  a n d  m R N A  ( B ) ,  a s  w e l l  a s  t y r o s i n e  h y d r o x y l a s e  O H )  m R N A  ( C )  o n  
t h e  s i d e  i p s i l a t e r a l  t o  t h e  l e s i o n .  T h i s  s u p p o r t s  t h e  a u t o r e c e p t o r  r o l e  o f  t h e  D 2  r e c e p t o r  i n  t h e  
m i d b r a i n  o f  t h e  r a t .  
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brain, and appear to be codistributed, and that chronic agonist or antagonist treatments 
fail to regulate i)2 receptor mRNA; finally, anatomic evidence is provided for an auto- 
receptor role of D2 receptors in the midbrain. 
The localization of total D2 receptor mRNA parallels that would be predicted based 
on past autoradiographic and immunohistochemical research identifying dopaminergic 
circuits in the brain (Boyson et al 1986; Wamsley et al 1989; Bouthenet et al 1987; 
Charuchinda et al 1987; Dawson et al 1988; Richfield et al 1987). In fact, we ar~ oh~ers 
(Meador-Woodruff et al 1989; Mengod et al 1989; Weiner and Brarm 1989; N a j l e ~ m  
et al 1989) have demonstrated D2 receptor mRN.~, in every traditional region of the brain 
implicated as a DA receptive field, reflecting postsynaptic receptor synthesis. These studies 
provide direct anatomic confirmation of the dopaminoceptive nature of t~se  various 
limbic and striatal regions, and in conjunction with the findings in the midbrain provide 
a more comprehensive anatomic understanding of these receptors. 
The parallel distributions of D2 receptor mRNA and binding sites provides some 
confirmation of previously defined DA circuits in the brain. In situ hybridization, however, 
is only capable of resolving the somata synthesizing a given retiNA, whereas receptor 
autoradiography can visualize distant axonal and dendritic receptor binding sites in ad- 
dition to receptors on the cell bodies themselves. The high degree of concordance of D2 
binding and message distributions in a number of structures is not unexpected, as the 
receptor itself may be expressed in close proximity to the cell body likely to synthesize 
it. Areas of striking dissimilarity between these distributions have been observed, es- 
pecially in the hippocampus, regions of cortex, and the olfactory bulb. We have previously 
speculated on the reasons for this observation (Mansour et al 1990a), and have proposed 
the differential localization of binding sites (on processes as well as cell bodies) and 
message (cell L, cdies only) and receptor transport as explanafigns of this phenomenon. 
The finding of D2 receptor mRNA in some DA-con~ining cell groups (i.e., the sub- 
stantia nigra, VTA, and zona incerta) by a number of groups (Mengod et al 1989; Weiner 
and Brann 1989; Najlerahim et al 1989), in addition to our own work, suggests that D2 
receptors may have an autoreceptor function. To confirm that the D2 receptor mRNA 
found in the midbrain could encode autoreceptors, we performed several additional stud- 
ies. We have been able to demonstrate that cells in the substantia nigra and VTA expressing 
D2 receptor mRNA also are positive for the presence of TH, a biochemical marker for 
catecholamine synthesis. This extensive colocalization of D2 receptor message and TH 
immunostaining strongly support the contention that this receptor in the midbrain has an 
autore~c~eptor function. To fi~%her confirm this, we performed 6-OHDA lesions. By in- 
fusing 6-OHDA into the medial forebrain bundle, the dopaminergic axons projecting 
from the midbrdin to the forebr.;in are spccificaiiy destrnyed. The coincident disappearance 
of all TH and D2 receptor n~d~lA, as well as all D2 receptor binding, in the substantia 
nigra and VTA supports the hypothesis hhat the D2 receptor mRNA in the midbrain is 
encoding autoreceptor synthesis. These findings are consistent with previous studies 
indicating that the DA autoreceptor is D2 in nature (Reisine et al 1979; White and Wang 
1983; S'~oef et al 1982; Brown et al 1985), and further suggest that most, if not all, 
midbrain DA cells are capable of synthesizing D2 autoreceptors. 
A number of DA-containing cell groups do not manifest D2 receptor mRNA, most 
notably the medullary periventdcular groups corresponding to AI4 and AI5. Whether 
this suggests that these systems do not contain autoreceptors is not clear. These are very 
small neurons (relative to nigral neurons), and a message of low abundance in such small 
cells might escape detection. Thus it is unclear if these groups lack autoreceptors, or 
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contain them but are undetected due to sensitivity problems of this technique. It is clear, 
however, that if autoreceptors are produced in AI4 and AiS, the message would be 
present at a considerably lower concentration than found in the substantia nigra, VTA, 
or the zona incerta. 
The discovery of at least two isoforms of D2 receptor mRNA originally caused consid- 
erable excitement, suggesting the possibility that the postsynaptic receptor was slightly dif- 
ferent from the autoreceptor, or that the postsynaptic receptors found in the motor (nigro- 
striatal) system were distinct from those in the more limbic structures. Such simple and 
elegant solutions are not the case, however, since both D2~ and D2~ mRNAs appear to be 
codistributed in every region of the brain examined. Certainly, these two forms both exist 
as autoreceptors and postsynaptic receptors, and appear to be distributed in all of the DA 
receptor fields, including the motor, limbic, and hypothalamic systems. It remains to be 
determined what significance these two forms represent. They have similar distributions, 
albeit the longer isoform is more abundant, and have similar ligand binding characteristics 
(Giros et al 1989; Grandy et al 1989; Monsma et al 1989; Chio et al 1990). The region of 
difference (exon 5) falls in the third cytosolic loop of the translated protein, and this is the 
locus of G-protein coupling in the seven-transmembrane domain receptors. Perhaps these 
two isoforms have subtle differences in G-protein binding and hence second messenger 
coupling. The exact nature of the difference between these forms awaits elucidation. 
Neither haloperidol nor apomorphine treatment caused significant changes in the levels 
of De receptor mRNA in the basal ganglia or in the substanfia nigra, as determined by in situ 
hybridization. This is in agreement with at least two other reports (van Tol et al 1990; Sri- 
vastava et al 1990), although a study has been published in which chronic haloperidol pro- 
moted a slight increase in D2 receptor mRNA in the striatum and other brain regions (Co'nini 
et al 1990). The reasons for these discrepancies are not yet clear, but it seems that any reg- 
ulation of De receptor mRNA by haloperidol is not particularly reproducible nor robust. The 
previously reported upregulation of D2 receptor binding following chronic haloperidol 
treatment (Burr et al 1977; Chipkin et al 1987; MacLennon et al 1988) may be the result of 
posttranslational as opposed to transcriptional events, but this remains to be clarified. None- 
theless, if the finding of a lack of regulation of this mRNA by chronic antagonist treatment 
is confirmed, it may be quite useful in the study of this marker in postmortem tissue from 
patients who had received chronic antipsychotic treatment. 
The data presented in this article tend te be consistent with our previous understanding 
of DA systems based on past receptor binding, immunohistochemical, and lesion studies. 
The studies described in this report do more than merely confirm these previous results, 
however, and offer important additional information relevant to the understanding of brain 
DA circuitry. For example, when a gene is first cloned, the technique of in situ hybridization 
identifies the anatomic distribution of the corresponding mRNA, which helps to confirm the 
identity of a given clone. Our results (Meador-Woodruff et al 1989) helped to solidify the 
identification of these particular clones as in fact encoding D2 receptors. As has been men- 
tioned previously, in situ hybridization only labels the cell bodies of origin of the receptors, 
in contrast to receptor autoradiography, which reveals a different anatomic pattern that in- 
cludes distant processes where receptor insertion into the cell membrane has occurred. This 
distinction allows the comparison of the locations of biosynthetic origin of a receptor versus 
its final destination, which will ultimately allow us to characterize the distinct cellular events 
of receptor synthesis, transport, and subsequent insertion into the cell membrane. Finally, 
the ability to measure mRNA levels in an anatomic context now allows the study of the 
regulation of the DA receptors at both the level of gene transcription (mRNA) and transla- 
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tion (final receptor protein). In fact, in situ hybridization has sufficient resolution to allow 
the determination of regulatory changes within a single ceil. 
In addition to this extension of our understanding of the brain DA systems, these studies 
have demonstrated the feasibility of examining the expression of the D2 receptor gene in an 
anatomic context, thus setting the stage for postmortem investigations in schizophrenia. 
The study of mRNA levels in postmortem brains may have certain advantages over the de- 
termination of neurotransmitters and other proteins. Messenger RNA levels tend to be quite 
stable in brain, requiring hours to days to change appreciably in concentration (Bimberg et 
al 1983). Thus, mRNA levels tend not to be altered rapidly at the time of death, unlike 
neurotransmitters, which may be acutely released, causing changes in receptor occupancy. 
In addition, the level of a given mRNA in the brain probably reflects the cumulative history 
of the particular system rather than the more recent terminal events, thus providing a glimpse 
of the underlying pathology or functioning of a given system. There is of course degradation 
of RNA after death, as there is degradation of enzymes and other proteins. Unlike proteins, 
however, mRNA degradation occurs in a somewhat predictable fashion, due to the ubiq- 
uitous distribution of the RNases, as opposed to the more heterogeneous dismbution of var- 
ious proteolytic enzymes in brain. Whether the study ~f D2 receptor mRNA in postmortem 
brain will reveal any differences of the expression of this gene in schizop~nia remains to 
be seen, but the studies themselves are feasible, and this should be an e~cirJng area of re- 
4 F  
search for the next few years. | 
This series of studies has begun to characterize the mRNA encircling the D- DA 
receptors in the central nervous system, and sets the stage for our next series of experiments 
aimed at examinLqg these ~¢epto~ dL,'ect!y in postmortem brains of patients who had 
schizophrenia. In addition to the I)2 receptors, a DA Dt receptor (Dearry et al 1990; Zhou 
et al 1990; Sunahara et al 1990; Monsm-_. et al 1990), and a so-called D3 receptor (Sokoloff 
et al 1990) have recently been cloned. We are aggressively pursuing the characterization 
of these and other dopamine receptor clones in brain as well. It is only with this fun- 
damental understanding of these multiple DA receptor types and forms, and the com- 
bination of molecular biological and traditional anatomic techniques, that we may ulti- 
mately be able to clarify the role of th~se receptors in '.he pathogenesis of schizophrenia. 
The cloning of the D2 receptors has provided a new set 3f tools with which we can test 
the dopamine hypothesis of schizophrenia, and heralds advances in our understanding of 
the genetic basis of this disease. 
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